바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.82 No.2
Citation Share

Correlation between GenoType MTBDR plus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2019, v.82 no.2, pp.143-150
https://doi.org/10.4046/trd.2018.0027



& (2019). Correlation between GenoType MTBDR plus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance. Tuberculosis & Respiratory Diseases, 82(2), 143-150, https://doi.org/10.4046/trd.2018.0027
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: The purpose of this study was to analyze the relationship between the gene mutation patterns by the GenoType MTBDRplus (MTBDRplus) assay and the phenotypic drug susceptibility test (pDST) results of isoniazid (INH) and prothionamide (Pto). Methods: A total of 206 patients whose MTBDRplus assay results revealed katG or inhA mutations were enrolled in the study. The pDST results were compared to mutation patterns on the MTBDRplus assay. Results: The katG and inhA mutations were identified in 68.0% and 35.0% of patients, respectively. Among the 134 isolated katG mutations, three (2.2%), 127 (94.8%) and 11 (8.2%) were phenotypically resistant to low-level INH, highlevel INH, and Pto, respectively. Among the 66 isolated inhA mutations, 34 (51.5%), 18 (27.3%) and 21 (31.8%) were phenotypically resistant to low-level INH, high-level INH, and Pto, respectively. Of the 34 phenotypic Pto resistant isolates, 21 (61.8%), 11 (32.4%), and two (5.9%) had inhA, katG, and both gene mutations. Conclusion: It is noted that Pto may still be selected as one of the appropriate multidrug-resistant tuberculosis regimen, although inhA mutation is detected by the MTBDRplus assay until pDST confirms a Pto resistance. The reporting of detailed mutation patterns of the MTBDRplus assay may be important for clinical practice, rather than simply presenting resistance or susceptibility test results.

keywords
katG Protein, InhA Protein, Isoniazid, Prothionamide, Genotype, Biological Assay, Disease Susceptibility, Research Design, Mycobacterium tuberculosis, Mycobacterium

Reference

1.

1. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13. Geneva: World Health Organization; 2016.

2.

2. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007; 11:571-6.

3.

3. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea, 2016. Cheongju:Korea Centers for Disease Control and Prevention; 2016.

4.

4. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis third edition, 2017. Cheongju: Korea Centers for Disease Control and Prevention; 2017.

5.

5. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. WHO/HTM/TB/2016.04. Geneva: World Health Organization; 2016.

6.

6. Leylabadlo HE, Kafil HS, Yousefi M, Aghazadeh M, Asgharzadeh M. Pulmonary tuberculosis diagnosis: where we are? Tuberc Respir Dis 2016; 79:134-42.

7.

7. Rouse DA, Li Z, Bai GH, Morris SL. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis . Antimicrob Agents Chemother 1995; 39:2472-7.

8.

8. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006; 55(Pt 11):1527-31.

9.

9. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis : a systematic review. PLoS One 2015; 10:e0119628.

10.

10. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol 2006; 44:3659-64.

11.

11. Gali N, Dominguez J, Blanco S, Prat C, Alcaide F, Coll P, et al. Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance. J Clin Microbiol 2006; 44:201-5.

12.

12. Lavender C, Globan M, Sievers A, Billman-Jacobe H, Fyfe J. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. Antimicrob Agents Chemother 2005; 49:4068-74.

13.

13. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47:3799-805.

14.

14. Engohang-Ndong J, Baillat D, Aumercier M, Bellefontaine F, Besra GS, Locht C, et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol Microbiol 2004; 51:175-88.

15.

15. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis . Science 1994; 263:227-30.

16.

16. Lee H, Cho SN, Bang HE, Lee JH, Bai GH, Kim SJ, et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis 2000; 4:441-7.

17.

17. Lin SY, Desmond E, Bonato D, Gross W, Siddiqi S. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009; 47:3630-4.

18.

18. Unissa AN, Selvakumar N, Narayanan S, Suganthi C, Hanna LE. Investigation of Ser315 substitutions within katG gene in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from south India. Biomed Res Int 2015; 2015:257983.

19.

19. van Doorn HR, de Haas PE, Kremer K, Vandenbroucke-Grauls CM, Borgdorff MW, van Soolingen D. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG:a decade of experience in The Netherlands. Clin Microbiol Infect 2006; 12:769-75.

20.

20. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis . PLoS Pathog 2006; 2:e61.

21.

21. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46:1417-24.

22.

22. Vilcheze C, Jacobs WR Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis : genes, mutations, and causalities. Microbiol Spectr 2014; 2:MGM2-0014-2013.

23.

23. Lei B, Wei CJ, Tu SC. Action mechanism of antitubercular isoniazid: activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J Biol Chem 2000; 275:2520-6.

24.

24. Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002; 277:12824-9.

25.

25. Machado D, Perdigao J, Ramos J, Couto I, Portugal I, Ritter C, et al. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother 2013; 68:1728-32.

26.

26. Larsen MH, Vilcheze C, Kremer L, Besra GS, Parsons L, Salfinger M, et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis , M. bovis BCG and M. tuberculosis . Mol Microbiol 2002; 46:453-66.

27.

27. Vilcheze C, Weisbrod TR, Chen B, Kremer L, Hazbon MH, Wang F, et al. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 2005; 49:708-20.

28.

28. Cardoso RF, Cardoso MA, Leite CQ, Sato DN, Mamizuka EM, Hirata RD, et al. Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil. Mem Inst Oswaldo Cruz 2007; 102:59-61.

29.

29. Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High prevalence of inhA promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. PLoS One 2015; 10:e0135003.

30.

30. Rueda J, Realpe T, Mejia GI, Zapata E, Rozo JC, Ferro BE, et al. Genotypic analysis of genes associated with independent resistance and cross-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2015; 59:7805-10.

31.

31. Tan Y, Su B, Zheng H, Song Y, Wang Y, Pang Y. Molecular characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in southern China. Front Microbiol 2017; 8:2358.

32.

32. Han SB, Jo Y, Yu JK, Kim Y, Park YJ. Performance assessment of Advansure MDR-TB Genoblot Assay Kit for anti-tuberculosis drug susceptibility test. Lab Med Online 2012; 2:34-40.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy